Medifast (NYSE:MED) Updates Q3 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its third quarter 2026 earnings guidance on Monday. The company provided EPS guidance of -0.650–0.150 for the period, compared to the consensus EPS estimate of -0.620. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $68.0 million. Medifast also updated its FY 2026 guidance to -1.750–0.250 EPS.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on MED shares. Weiss Ratings restated a “sell (e+)” rating on shares of Medifast in a research note on Monday. Zacks Research upgraded shares of Medifast from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $12.00.

Medifast Stock Up 34.7%

MED opened at $13.12 on Wednesday. The business has a fifty day simple moving average of $11.06 and a 200-day simple moving average of $11.05. The firm has a market cap of $145.86 million, a PE ratio of -7.17 and a beta of 0.65. Medifast has a fifty-two week low of $9.22 and a fifty-two week high of $15.11.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 6.63% and a negative net margin of 8.08%.The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, equities research analysts anticipate that Medifast will post -1.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Scott Schlackman acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $12.53 per share, with a total value of $31,325.00. Following the purchase, the director owned 30,549 shares of the company’s stock, valued at approximately $382,778.97. This trade represents a 8.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Medifast

A number of institutional investors have recently bought and sold shares of the business. Lido Advisors LLC acquired a new position in shares of Medifast in the 3rd quarter valued at about $4,521,000. Steamboat Capital Partners LLC acquired a new position in Medifast in the 4th quarter valued at approximately $2,952,000. Charles Schwab Investment Management Inc. lifted its position in Medifast by 30.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after buying an additional 181,618 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Medifast by 37.4% in the second quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock worth $5,569,000 after acquiring an additional 107,854 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Medifast during the third quarter valued at $867,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.